NCT05400395

Clinical Trial for GNX80 in Intermittent Claudication

A Prospective, Randomized, Placebo-controlled, Double-blinded, Multi-center, Phase IV, Exploratory Clinical Trial to Demonstrate the Effect of Improving the Walking Distance by GNX80 in Patients With Intermittent Claudication

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: SK Chemicals Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 4, randomized clinical trial to evaluate whether GNX80 vs. placebo, prescribed for 6 months to patients with Intermittent Claudication(IC) would lead to an improvement in the walking distance.

Detailed description

A Prospective, Randomized, Placebo-controlled, Double-blinded, Multi-center, Phase IV, Exploratory Clinical Trial to Demonstrate the Effect of Improving the Walking Distance by GNX80 in Patients with Intermittent Claudication

Conditions

• Intermittent Claudication

Interventions

Type	Name	Description
DRUG	GNX80	GNX80 oral intake(BID) for 24 weeks
DRUG	Placebo	Placebo oral intake(BID) for 24 weeks

Timeline

• Start date: 2022-09-05
• Primary completion: 2024-03-01
• Completion: 2024-08-01
• First posted: 2022-06-01
• Last updated: 2022-10-27

Locations

1 site across 1 country: South Korea